Cenibra is our sales and distribution partner for Imperacer® Services, Assay Development Kits and Imperacer® Workstations in Europe.
Quanterix is a company that’s digitizing biomarker analysis to advance the science of precision health. The company’s digital health solution, Simoa, is changing the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. In doing so, Quanterix enables much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.
KPI Therapeutics is developing potentially game changing autoimmune therapies. Their platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Their lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as atopic dermatitis, myositis, and lupus, KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments.
Kineta® is an internationally-recognized biotechnology company focused on developing high need therapeutics in three large disease areas: autoimmune disease, viral disease and chronic pain.
German Sports University Cologne and Chimera Biotec support eachother's research on gene-doping and molecular pathways to identify doping. This research field is also supported by the World-Anti-Doping-Agency.